Novel Therapeutics for Multiple Myeloma
|
|
- Piers Garrison
- 6 years ago
- Views:
Transcription
1 Novel Therapeutics for Multiple Myeloma Marc S. Raab, MD Max-Eder-Group Experimental Therapies for Hematologic Malignancies Department of Medicine V, Heidelberg University Medical Center & German Cancer Research Center (DKFZ)
2 Novel Therapeutics success 1,056 patients grouped into and cohorts Survival improved over time, particularly in patients aged > 65 years (p = 0.001) Proportion surviving 1.0 Diagnosed Diagnosed Follow-up from diagnosis (years) Survival Median OS, years 4.6 NR year survival, % year estimated OS, % Overall > 65 years < 65 years NS p Kumar SK, et al. Blood. 2012;120:[abstract 3972]. Updated data presented at IMW2013.
3 Novel Therapeutics unmet medical need Patients refractory to bortezomib and relapsed or refractory to or ineligible to immunomodulatory drugs 100 Percentage (%) Median PFS: 5 months (range 4 6) Median OS: 9 months Months Kumar SK, et al. Leukemia. 2012;26:
4 Novel agents against myeloma Immunmodulators Thalidomide Lenalidomide Pomalidomide Proteasome-Inhibitors Bortezomib Carfilzomib Monoclonal ABs Elotuzumab Tabalumab Daratumumab Siltuximab BHQ880 MOR202
5 The second generation proteasome inhibitor: Carfilzomib Tetrapeptide epoxyketone Novel proteasome inhibitor Binds the β5 and β5 i subunits irreversibly H O H O N N N N N O O H O H O Carfilzomib Active against bortezomib-resistant MM cell lines and samples from pts with bortezomib resistance [1] O Well tolerated in phase II investigation [2] Active alone and in a number of combinations [3] in relapsed/refractory MM, as well as in initial therapy Recently FDA approved for rel/ref MM in US 1. Kuhn DJ, et al. Blood. 2007;110: O Connor OA, et al. Clin Cancer Res. 2009;15: Vij R, et al. Blood. 2012;[Epub ahead of print].
6 Carfilzomib: Phase II Studies efficacy Patients, % Relapsed and refractory MM 003-A1 (73% BORT-refractory) Single agent + dex premed (N = 257) 5 18 Relapsed and/or refractory MM 004 (BORT-naive) Single agent (N = 67) Relapsed MM 006 (75% prior BORT) CFZ + Rd (N = 51) VGPR PR MR 0 13 Median 5 prior treatments Median 2 prior treatments 1 3 prior treatments Direct comparisons across studies are not possible, given differences in study design and patient populations. 12 Siegel D, et al. Blood. 2012;120: Vij R, et al. Blood. 2012;119: Wang M, et al. J Clin Oncol. 2011; 29:[abstract 8025]. Updated data presented at ASCO
7 Carfilzomib: Phase II Studies safety Incidence and severity of treatment-emergent adverse events ( 25%) and carfilzomib-related adverse events (n = 266) Adverse events Haematological All grades, n (%) Grades 3 or 4, n (%) All grades carfilzomibrelated, n (%) Anaemia 122 (46) 63 (24) 59 (22) Thrombocytopenia 103 (39) 77 (29) 77 (29) Lymphopenia 62 (23) 52 (20) 44 (17) Neutropenia 48 (18) 29 (11) 40 (15) Leukopenia 37 (14) 18 (6.8) 31 (12) Non-haematological Fatigue 130 (49) 20 (7.5) 98 (37) Other important toxicities included transient renal impairment and shortness of breath as well as hypertension and rare cases of significant cardiac dysfunction Siegel D, et al. Blood. 2012;120: ; updated at IMW2013
8 Other Novel Proteasome Inhibitors Marizomib and Ixazomib: 2 nd generation proteasome inhibitors with promising activity in RRMM: Marizomib (NPI 0052): induces apoptosis in cell lines resistant to conventional and bortezomib based therapies 1 in animal models, NPI 0052 was well tolerated and prolonged survival 1 active in RRMM patients (ORR ~ 25% at MTD +/ dex) 3 Ixazomib (MLN9708): shows selective anti MM activity in cell lines and an animal model 2 is currently being tested in clinical trials, with promising activity, esp. in combination, and has favourable tolerability 4 1. Chauhan D, et al. Cancer Cell. 2005;8: Chauhan D, et al. Clin Cancer Res. 2011;17: ; 3. Richardson et al, Blood Kumar et al., Blood. 2012;120:[abstract 332].
9 Pomalidomide: Third Generation of IMiDs Pomalidomide: novel immunomodulatory agent structurally similar to thalidomide and lenalidomide [1] Distinct safety and efficacy profile Improved potency Clinical activity after use of bortezomib and lenalidomide shown in relapsed/refractory myeloma MTD: 2 mg once daily, 5 mg every other day, 4mg daily [1,2,4] Phase II data showed efficacy in combination with lowdose dexamethasone in relapsed myeloma patients [3] Recently approved for rel/ref MM in US NH 2 O O H N 1. Schey SA, et al. J Clin Oncol. 2004;22: Streetly MJ, et al. Br J Haematol. 2008;141: Lacy MQ, et al. J Clin Oncol. 2009;27: Richardson PG, et al. ASH 2010 O N O
10 Pomalidomide: MM 003 Trial N = 455 Age 18 yrs 2 prior therapies Refractory to last treatment Refractory, intolerant or relapsed 6 mos (if PR) to BORT and LEN POM + LoDEX (n = 302): POM: 4 mg, d1 21 LoDEX: 40 mg ( 75 y) or 20 mg (> 75 y), d1, 8, 15, day cycles HiDEX (n = 153): HiDEX: 40 mg ( 75 y) or 20 mg (> 75 y) d1 4, 9 12, day cycles PD or intolerable AE PD Follow up for OS and SPM until 5 years postenrollment Companion trial MM 003C POM 21/28 days Primary endpoint: PFS Key secondary endpoints: OS, ORR ( PR), DoR, safety Dimopoulos MA, et al. Blood. 2012;120:[abstract LBA-6]. Updated data presented at IMW2013.
11 Pomalidomide: MM 003 Trial PFS ITT population LEN- and BORT-refractory Median PFS Median PFS POM + LoDEX (n = 302) 3.6 months POM + LoDEX (n = 221) 3.2 months Proportion of patients HiDEX (n = 153) 1.8 months HR = 0.45 p< PFS (months) Proportion of patients HiDEX (n = 108) 1.7 months HR = 0.48 p< PFS (months) ITT: intent-to-treat. Dimopoulos MA, et al. Blood. 2012;120:[abstract LBA-6]. Updated data presented at IMW2013.
12 Pomalidomide: MM 003 Trial overall survival ITT population* LEN- and BORT-refractory* Median OS (95% CI) Median OS (95% CI) POM + LoDEX (n = 302) NR (11.1 NE) POM + LoDEX (n = 221) NR (8.5 NE) 1.0 HiDEX (n = 153) 7.8 months ( ) 1.0 HiDEX (n = 108) 7.4 months ( ) Proportion of patients HR = 0.53 p< OS (months) Proportion of patients HR = 0.56 p = OS (months) * 29% of pts received POM after progressing on HiDEX. ITT: intent-to-treat Dimopoulos MA, et al. Blood. 2012;120:[abstract LBA-6]. Updated data presented at IMW2013.
13 Pomalidomide: MM 003 Trial safety Discontinuation due to AEs: 7% POM + LoDEX; 6% HiDEX VTE, all grades: 3% POM + LoDEX; 2% HiDEX Peripheral neuropathy, all grades: 12% POM + LoDEX; 11% HiDEX Grade 3 and 4 AEs, % POM + LoDEX (n = 300) HiDEX (n = 149) Neutropenia Febrile neutropenia 7 0 Anaemia Thrombocytopenia Infections Pneumonia 9 7 Haemorrhage 3 5 Glucose intolerance 3 7 Fatigue 5 5 Dimopoulos MA, et al. Blood. 2012;120:[abstract LBA-6]. Updated data presented at IMW2013.
14 Target Antibody Company Type CS1 Elotuzumab Abbot/BMS Humanized IL 6 Siltuximab Orthobiotec Chimeric CD138 BT062 Biotest Chimeric; conjugated to Maytansinoid Anti KIR IPH2101 Innate Pharma Fully Human CD40 SGN 40, HCD122 Dacetuzumab, Lucatumumab Seattle Genetics Novartis Humanized Fully Human CD56 IMGN901, Lorvotuzumab Meransine ImmunoGen Humanized; conjugated to Maytansinoid CD38 MOR202 MorphoSys Fully Human CD38 Daratumumab Genmab Fully Human RANKL Denosumab Amgen Fully Human DKK 1 BHQ880 Novartis Fully Human FGFR3 PRO 001 Prochon Biotech Genetech Humanized BAFF Ly Lilly Fully Human
15 Daratumumab Phase I/II Study in Relapsed/Refractory MM Daratumumab: anti-cd38 antibody; kills MM cells via ADCC, CDC, and induction of apoptosis Patients: relapsed/refractory MM ( 2 different therapies), not eligible for ASCT; 3 patients/dosing group Efficacy based on serum and/or urine M-component analyses Weekly x 8 w followed by /14d up to week 24w (MTD: 8 mg/kg) In 15 of 32 (47%).reduction in paraprotein (following 8 w of Dara in doses up to 24mg/kg) 4 PR (13%) + 6 MR (19%) + 5 SD At doses > 4mg/kg, 8 of the 12 (66%) had at least a MR Adverse events were manageable Plesner T, et al. ASCO Abstract 8019.
16 Daratumumab Phase I/II Study in Relapsed/Refractory MM Reletive change in paraproteine from baseline (%) mg/kg 2 mg/kg 4 mg/kg 8 mg/kg 16 mg/kg 24 mg/kg C C A A A A A A B C A A C A A B A C A A A A A A B A B A A C A C Patient number Plesner T, et al. ASH Abstract 8019, updated at IMW2013
17 A Phase 2 Study of Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Sagar Lonial, 1,2 Andrzej J. Jakubowiak, 1,3 Sundar Jagannath, 1,4 Marc S. Raab, 5 Thierry Facon, 6 Ravi Vij, 1,7 Philippe Moreau, 8 Donna E. Reece, 9 Darrell White, 10 Lotfi Benboubker, 11 Jeffrey Zonder, 12 Jean-Francois Rossi, 13 Claire Tsao, 14 Teresa Parli, 14 Glenn Kroog, 15 Anil K. Singhal, 14 Paul G. Richardson, 1,16 on behalf of the 1703 Study Investigators 1 Multiple Myeloma Research Consortium, Norwalk, CT, USA; 2 Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA; 3 University of Michigan, Ann Arbor, MI, USA; 4 Mount Sinai Medical Center, New York, NY, USA; 5 Universitaetsklinikum Heidelberg, Heidelberg, Germany; 6 Hopital Claude Huriez, Service des Maladies du Sang, Lille, France; 7 Washington University School of Medicine, St. Louis, MO, USA; 8 Hematology Department, University Hospital, Nantes, France; 9 Princess Margaret Hospital, Toronto, Ontario, Canada; 10 Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada; 11 CHU Tours-Hopital Bretonneau, Tours, France; 12 Karmanos Cancer Institute, Detroit, MI, USA; 13 CHU de Montpellier- Hopital Saint-Eloi, Montpellier, France; 14 Abbott Biotherapeutics Corporation, Redwood City, CA, USA; 15 Bristol-Myers Squibb, Princeton, NJ, USA; 16 Dana-Farber Cancer Institute, Boston, MA, USA
18 Elotuzumab efficacy Elotuzumab 10 mg/kg Elotuzumab 20 mg/kg Total Patients, n ORR ( PR), n (%) 33 (92) 28 (76) 61 (84) CR/stringent CR, n (%) 5 (14) 4 (11) 9 (12) VGPR, n (%) 17 (47) 14 (38) 31 (43) PR, n (%) 11 (31) 10 (27) 21 (29) <PR, n (%) 3 (8) 9 (24) 12 (16) Overall median time to response: 1 month (range, ) Overall median time to best response: 2.5 months (range, ) Median duration of objective response: 17.8 months (range, ) Richardson PG, et al. ASH Abstract 202.
19 Elotuzumab efficacy Proportion of Progression Free Patients (%) Median Time to Progression/Death: 10 mg/kg (n=36): not yet reached 20 mg/kg (n=37): 18.6 mos (95% CI ) 10 mg/kg Number at Risk: Months At a median follow-up of 20.8 months, median PFS has not been reached in the 10 mg/kg arm 20 mg/kg Preliminary median PFS of 26.9 months was reported in the abstract; after 2.7 months of additional follow-up, no new PD or death reported. These pts had an increased PFS duration, and in the updated analysis, median PFS was not yet reached Richardson, et al ASH Abstract Updated data presented at IMW2013.
20 Outlook Future of Myeloma Therapy Major advances: Bortezomib, Thalidomid, Lenalidomid 2nd Generation : Carfilzomib, Pomalidomid => major advances? more bullets in the pocket, but head-to-head comparisons are missing Antibodies: promising, but no phase III data yet Personalized therapy
21 Cereblon Predicts Sensitivity to Lenalidomid Lenalidomide resistant myeloma cells lack cereblon CRBN actin MM1.S MM1.S res Zhu YX, et al. Blood. 2011;118:
22 Cereblon Predicts Sensitivity to Lenalidomid Gene Expression Levels of Cereblon Predict PFS of Pomalidomide Treated Patients P= months versus 17 months Schuster SR, et al. Blood 2012;120:[abstract 194].
23 Cereblon Predicts Sensitivity to Thalidomid A Progression free survival C Progression free survival > median < median Months > median < median p = Months A-B: thal-treated, C-D: bort-treated p = B Overall survival D Overall survival > median < median Months > median < median Months p = p = Broyl A, et al. Blood. 2013;121:
24 Cereblon Predictor for Sensitivity to IMiDs? MM1.S OPM2 KMS11 JJN3 OCIMY5 OPM1 SKMM2 KMS12PE MM1.S res CRBN -actin Zhu YX, et al. Blood. 2011;118:
25 Signaling in Myleoma Morgan et al., NatRevCan 2012
26 BRAF V600E, 2 4% in myeloma Cancer Discovery 2013.
27 Figure 2 BRAF V600E, 2 4% in myeloma #1 lines of therapy 1 st line #2 2 nd line 3 rd line #3 4 th line vemurafenib #4 remission BRAF V600E status #5 #6 mutated wildtype subclone extramedullary disease # Years after diagnosis of multiple myeloma Cancer Discovery
28 Clinical Inhibition of BRAF V600E Cancer Discovery 2013.
29 Clinical Inhibition of BRAF V600E Cancer Discovery 2013.
Elotuzumab is a humanized monoclonal antibody designed to treat multiple myeloma (MM)
A Phase 2 Study of in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/ Refractory Multiple Myeloma: Updated Results Paul G. Richardson, 1,2 Sundar Jagannath, 2,3 Philippe
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3
The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationTreatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationUnderstanding the cellular targets of IMiDs and the relevance to clinical efficacy Dr. A. Keith Stewart
Understanding the cellular targets of IMiDs and the relevance to clinical efficacy Dr. A. Keith Stewart Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Molecular Structure of Thalidomide,
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients With to 3 Prior Lines of Therapy Based on
More informationDaratumumab: Mechanism of Action
An Open-label, Randomised, Phase 3 Study of Daratumumab, Lenalidomide, and Dexamethasone (D) Versus Lenalidomide and Dexamethasone () in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX* Meletios
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationRecent Advances in the Treatment & Management of Relapsed Refractory Multiple Myeloma.
Recent Advances in the Treatment & Management of Relapsed Refractory Multiple Myeloma. Ajay Nooka MD MPH Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory University
More informationAbstract. Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY, USA; 2 Hospital-12-de-Octubre, Madrid, Spain; 3
Daratumumab, Carfilzomib, and Dexamethasone (D-Kd) in Lenalidomiderefractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY11 Chari A, 1* Martinez-Lopez J, 2 Mateos M-V, 3 Bladé
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationNew drugs in multiple myeloma role of carfilzomib and pomalidomide
Carfilzomib (CFZ), an epoxyketone with specific chymotrypsin-like activity, is a second-generation proteasome inhibitor with significant activity in patients with relapsed and refractory multiple myeloma.
More informationPomalidomide: a new hope for relapsed and refractory multiple myeloma
4 Pomalidomide: a new hope for relapsed and refractory multiple myeloma C. Doyen, MD 1 Relapsed and refractory multiple myeloma patients have a particularly poor prognosis and the development of new drugs
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationConflict of Interest Disclosure Form
Conflict of Interest Disclosure Form NAME : Niels van de Donk MD-PhD AFFILIATION: University of California San Francisco. In accordance with the rules of the Health Care Inspectorate (IGZ), speakers are
More informationNew Drugs on the Horizon Providing Hope for Multiple Myeloma Patients Kenneth C. Anderson, M.D.
New Drugs on the Horizon Providing Hope for Multiple Myeloma Patients Kenneth C. Anderson, M.D. Kraft Family Professor of Medicine Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationDevelopments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D.
Developments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D. Kraft Family Professor of Medicine Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationHorizon Scanning Centre November Pomalidomide for multiple myeloma third line SUMMARY NIHR HSC ID: 4436
Horizon Scanning Centre November 2012 Pomalidomide for multiple myeloma third line SUMMARY NIHR HSC ID: 4436 This briefing is based on information available at the time of research and a limited literature
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationCity of Hope, Duarte, CA, USA; 11 Columbia University Medical Center, New York, NY, USA. 1
Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With 2 Lines of Prior Therapy and Refractory or Relapsed and Refractory Multiple Myeloma
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2 Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3
Ibrutinib in Combination With Low-Dose Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma: Results From a Multicenter Phase 2 Trial Paul G. Richardson, MD 1 *, William
More informationMultiple Myeloma New Trials and New Drugs. Rafat Abonour, M.D.
Multiple Myeloma New Trials and New Drugs Rafat Abonour, M.D. Treatment Combinations Then and Now NEW VD Rev/Dex CyBorD VTD VRD CDR SCT VD/VRD Lenalidomide Bortezomib Bortezomib Lenalidomide Thalidomide
More informationAt Fox Chase Cancer Centre during study participation
Long-Term Outcome of a Phase 1 Study of the Investigational Oral Proteasome Inhibitor Ixazomib at the Recommended Phase 3 Dose in Patients with Relapsed or Refractory Systemic Light-Chain (AL) Amyloidosis
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationPhase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma Jatin J Shah, MD 1, Robert Z. Orlowski, MD, PhD 1, Raymond Alexanian, MD 1, Michael
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationMultiple Myeloma. Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario
Multiple Myeloma Dr. Janet MacEachern BA, MD, FRCP(C) Grand River Regional Cancer Center Kitchener, Ontario Disclosures Relationships with financial sponsors: Grants/Research Support: n/a Speakers Bureau/Honoraria:
More informationDARA Monotherapy Studies
Usmani, SZ. Blood. 26. http://dx.doi.org/.82/blood-26-3-752. Lokhorst HM, et al. N Engl J Med. 25;373(3):27-29. Lonial S, et al. Lancet. 25. I DARA Monotherapy Studies Baseline Characteristics Median (range)
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationDose-Dependent Efficacy of Daratumumab as Monotherapy in Patients with Relapsed or Refractory Multiple Myeloma
Dose-Dependent Efficacy of Daratumumab as Monotherapy in Patients with Relapsed or Refractory Multiple Myeloma Henk Lokhorst, Jacob Laubach, Hareth Nahi, Torben Plesner, Peter Gimsing, Markus Hansson,
More informationClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
ClaPD (Clarithromycin/[Biaxin ], Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma Tomer Mark 1, Angelique Boyer 1, Adriana Rossi 1, Manan Shah 1, Roger Pearse 1, Faiza Zafar
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationMultiple Myeloma Highlights: 2016 ASH Annual Meeting Patient Webinar
2016 ASH Annual Meeting Patient Webinar January 11, 2017 1 Welcome and Introductions Anne Quinn Young, MPH Vice President, Development and Strategic Partnerships Multiple Myeloma Research Foundation 2
More informationMultiple Myeloma: Update from ASH. Kenneth C. Anderson, M.D. Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard Medical School
Multiple Myeloma: Update from ASH Kenneth C. Anderson, M.D. Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard Medical School Integration of Novel Therapy Into Myeloma Management
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationFuture Strategies For Refractory Myeloma. Marc S. Raab
Future Strategies For Refractory Myeloma Marc S. Raab Multiple Myeloma Clonal proliferation of malignant plasma cells. excess bone marrow plasma cells monoclonal protein osteolytic bone lesions renal disease
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationBest of ASH 2017 DR. BRIAN DURIE. Brian GM Durie, MD Thursday, January 11, 2018
Best of ASH 2017 DR. BRIAN DURIE Brian GM Durie, MD Thursday, January 11, 2018 1 ASH Overview 2017 Total myeloma abstracts: 981 Important/Interesting: oral ~40 posters ~60 100 2 Which abstracts impact
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationClinicalTrials.gov Identifier: NCT
Subcutaneous Delivery of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase 1b Study Ajai Chari, 1 Hareth Nahi, 2 Maria-Victoria
More informationCOMy Congress A New Era of Advances in Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
A New Era of Advances in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationThe TOURMALINE-MM1 study: results and expert insights
The TOURMALINE-MM1 study: results and expert insights Professor Faith Davies UAMS Myeloma Institute, Arkansas, USA This educational meeting was organised and fully funded by Takeda UK Ltd. Takeda medicines
More informationUpdates in Multiple Myeloma: 12 months in 10 minutes
Updates in Multiple Myeloma: 12 months in 10 minutes Aaron Rosenberg MD, MS Assistant Prof. Medicine UC Davis Comprehensive Cancer Center Division of Hematology and Oncology Outline Standard of care for
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationPhase 1, Multicenter, Open-label, Doseescalation,
Phase 1, Multicenter, Open-label, Doseescalation, Combination Study of Pomalidomide (POM), Marizomib (MRZ), and Dexamethasone (Lo-Dex) in Patients with Relapsed and Refractory Multiple Myeloma Study NPI-0052-107
More informationClinicalTrials.gov Identifier: NCT
Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Lines of Therapy: Updated Analysis of CASTOR Maria-Victoria
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationHematologic Malignancies: Top Ten Advances Impacting Clinical Practice
Hematologic Malignancies: Top Ten Advances Impacting Clinical Practice Adam D. Cohen, MD Abramson Cancer Center University of Pennsylvania June 14, 2018 Please note that some of the studies reported in
More informationAn Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma
An Open-label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma Philippe Moreau, MD; Maria-Victoria Mateos, MD, PhD; Joan Bladé,MD; Lotfi
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationIntegration of Novel Therapy Into Myeloma Management
Updates on Diagnostic Criteria and Management of Multiple Myeloma Kenneth C. Anderson, MD Dana-Farber Cancer Institute Integration of Novel Therapy Into Myeloma Management Bortezomib, lenalidomide, thalidomide,
More informationChallenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies
Challenges in Distinguishing Clinical Signals to Support Development Decisions: Case Studies David Feltquate MD, PhD Head of Early Clinical Development, Oncology Bristol-Myers Squibb, Princeton, NJ Challenges
More informationWhere to go from Here and Future Trials?
Where to go from Here and Future Trials? Does our understanding of Pathogenesis, Disease management and Novel drugs get us closer to a cure of MM? Thierry FACON, MD Professor of Hematology Service des
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationStudy Rationale. Reference: Chanan-Khan, A., et al., ASH 2010, Abstract#1962. Reference: Whiteman, K., et al, AACR, 2009, Abstract#2799
Phase I Study of Lorvotuzumab Mertansine (LM) in Combination with Lenalidomide and Dexamethasone in Patients with CD56-Positive Relapsed or Relapsed/Refractory Multiple Myeloma (MM) Jesus Berdeja 1, Francisco
More informationCurrent treatment options for relapsed/refractory multiple myeloma in practice
Current treatment options for relapsed/refractory multiple myeloma in practice Professor Marίa-Victoria Mateos University Hospital of Salamanca, Salamanca, Spain Please note that discussion throughout
More informationMonoclonal antibodies and multiple myeloma Pr Philippe Moreau Nantes, France
Monoclonal antibodies and multiple myeloma Pr Philippe Moreau Nantes, France Disclosures Advisory boards and honoraria: Janssen, Takeda, Celgene, BMS, Novartis, Amgen Stockholder: no Rituximab + CHOP in
More informationTherapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz
Therapie des Multiplen Myeloms Alles im Fluss? Peter Neumeister, MD Division Hematology Medical University Graz 15.6.218 Newly Diagnosed Multiple Myeloma Transplant Eligible NDMM TE VCD is preferable to
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationJanssen Hematologic Malignancy Portfolio
Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in
More informationRelapsed/ Refractory Myeloma - update. Sep 2015
Relapsed/ Refractory Myeloma - update Sep 2015 Natural History of MM Asymptomatic Symptomatic M Protein (g/l) 100 50 20 MGUS or smoldering myeloma ACTIVE MYELOMA 1. RELAPSE Plateau remission 2. RELAPSE
More informationEnrique M. Ocio. University Hospital & Cancer Research Center University of Salamanca. Institute of Biomedical Research of Salamanca
Institute of Biomedical Research of Salamanca University of Salamanca Cancer Research Center IMiDs Enrique M. Ocio University Hospital & Cancer Research Center University of Salamanca History of Thalidomide,
More informationRelapsed Myeloma Sequencing Treatments
Relapsed Myeloma Sequencing Treatments Noopur Raje, MD Director, Center for Multiple Myeloma MGH Cancer Center Professor of Medicine Harvard Medical School Disclosures Consultant /Advisory Board: Celgene,
More informationManaging Major Adverse Events in Relapsed/Refractory Multiple Myeloma
Welcome to Managing Myeloma. I am Dr. Ajay Nooka. In today's presentation, I will discuss managing major adverse events in relapsed/refractory multiple myeloma. In this video, I will provide you with information
More informationMethods: Studies included in the analysis
Efficacy and safety of long-term ixazomib maintenance therapy in patients with newly diagnosed multiple myeloma not undergoing transplant: An integrated analysis of four phase 1/2 studies Meletios A. Dimopoulos,
More informationMultiple Myeloma: Approach to the Elderly
Multiple Myeloma: Approach to the Elderly Peter Anglin MD, FRCPC, MBA Stronach Regional Cancer Centre Newmarket, ON PMH Myeloma Day May 12, 2017 Peter Anglin MD Disclosures Speakers Bureau Advisory Boards
More informationUpdates in the Treatment and Management of Relapsed/Refractory Multiple Myeloma
Updates in the Treatment and Management of Relapsed/Refractory Multiple Myeloma Rachid Baz, MD Associate Professor, Departments of Oncologic Sciences and Medicine University of South Florida Associate
More informationA Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma
A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma P.G. Richardson, 1 R. Schlossman, 1 N. Munshi, 1 D. Avigan, 2 S. Jagannath, 3 M. Alsina,
More information